Inclusion Criteria:  The subject is between 18 and 75 years of age when written informed consent is obtained. Complaint of persistent or recurrent low back pain, with or without equal or lesser leg pain, for at least 90 days prior to Screen. Received at least 90 days of documented pain management care to address the primary pain complaint, prior to Screening (e.g. medication, physical therapy.) Diagnosed with chronic neuropathic pain of the low back and legs (of neuropathic origin only). Eligible candidate for SCS from a psychological and psychiatric standpoint as determined prior to Baseline Visit, per site's routine screening process No back surgery within 6 months prior to Screening. Average low back pain intensity, during the position/activity, which routinely causes worst pain, of 5 or greater on a 0-10 numerical rating scale during Baseline period based on eDiary. If taking prescription opioids for primary chronic pain complaint (low back and/or leg pain), must have been on a stable prescription (same drug(s) and dose(s)) 30 days prior to Screening to a total of less than 180 mg Oral Morphine equivalent. Willing and able to comply with all protocol-required procedures and assessments/evaluations (e.g. willing to comply with opioid prescription lock from the Baseline visit through End of Rate Randomization and protocol required stimulation parameter locks, complete daily eDiary). If female of childbearing potential: not pregnant, as evidenced by a negative pregnancy test at Screening. Subject signed a valid, IRB-approved informed consent form (ICF) provided in English.  Exclusion Criteria:  Significant cognitive impairment at Screening that, in the opinion of the Investigator, would reasonably be expected to impair the study candidates to participate in the study Have untreated major psychiatric comorbidity, serious drug related behaviour issues. Previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator). Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study Currently on any anticoagulant medications that cannot be discontinued during perioperative period Current condition associated with risk of immunocompromised that might increase risk of infection during study duration. A female who is pregnant, is breastfeeding, or is of childbearing potential and planning to get pregnant during the study or not using adequate contraception. Primary pain complaint of vascular origin (e.g. peripheral vascular disease). Spinal pain secondary to neoplasm, infection, autoimmune disorder with spinal involvement, or a spinal metabolic disorder. Clinically significant lumbosacral stenosis which would interfere with lead placement Prior history of lumbar-sacral spine fusion Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment might confound reporting of study outcomes (e.g. pelvic pain, angina pain, chronic migraine. Radiographic evidence of spinal instability requiring fusion Terminal illness with anticipated survival 1 year.